RLYB114
Ophthalmic Diseases
Complement dysregulation has been shown to be a driver of ocular inflammation, contributing to vision loss in diseases, such as age-related macular degeneration (AMD), where significant unmet medical needs remain.
RLYB114 Potential Indications
Ophthalmic diseases, including inflammatory and degenerative disorders, in which complement dysregulation is a central or major factor
Disease Mechanism
Over-activation of C5 is associated with ocular inflammation, tissue damage, and autoimmunity seen in diverse disease states.
Therapeutic Modality
C5-targeted Affibody® molecule conjugated to PEG (polyethylene glycol) to extend half-life
Mechanism of Action
Designed to provide inhibition of C5, the fifth and terminal component of the complement pathway
Mode of Administration
Intravitreal administration
RLYB114
Given the role of the complement system in retinal and ocular pathology, Rallybio is exploring ophthalmic diseases, including inflammatory and degenerative disorders, for the development of RLYB114.
Rallybio also recently (February 2023) broadened its research on ophthalmology through a collaboration with EyePoint Pharmaceuticals. The two companies are evaluating sustained intraocular delivery of Rallybio’s C5 inhibitor using EyePoint’s proprietary Durasert® technology, with an initial focus on an advanced form of AMD known as geographic atrophy.